Literature DB >> 35103880

CSF markers of AD-related pathology relate specifically to memory impairment in older people with HIV: a pilot study.

Judith D Lobo1, David J Moore2, Mark W Bondi2,3, Virawudh Soontornniyomkij2, Benchawanna Soontornniyomkij2, Ben Gouaux2, Cristian L Achim2,4, Ronald J Ellis5, Erin E Sundermann2.   

Abstract

Given the co-occurrence of memory impairment in HIV-associated neurocognitive disorders (HAND) and amnestic mild cognitive impairment/Alzheimer's disease (aMCI/AD), biomarkers are needed that can disentangle these conditions among people with HIV (PWH). We assessed whether cerebrospinal fluid (CSF) markers of AD could help in this effort by determining their relationship to learning and memory deficits versus cognitive deficits more characteristic of HAND than aMCI/AD (processing speed and complex visual/motor coordination) among 31 older PWH. CSF amyloid-β42 phosphorylated-tau, amyloid-β40/amyloid-β42 and phosphorylated-tau/amyloid-β42 ratio related to learning/memory performance but not HAND-related deficits, suggesting that these biomarkers may have utility in disentangling aMCI/AD from HAND.
© 2022. Journal of NeuroVirology, Inc.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid; Biomarkers; HIV-associated neurocognitive disorders; Mild cognitive impairment; Tau

Mesh：

Substances：

Year:  2022        PMID： 35103880      PMCID： PMC9081235          DOI： 10.1007/s13365-021-01048-x

Source DB:  PubMed          Journal:  J Neurovirol        ISSN： 1355-0284            Impact factor:   3.739


  35 in total

1.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

2.  CSF amyloid beta42 and tau levels correlate with AIDS dementia complex.

Authors:  B J Brew; L Pemberton; K Blennow; A Wallin; L Hagberg
Journal:  Neurology       Date:  2005-11-08       Impact factor: 9.910

Review 3.  NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation.

Authors:  T G D'Aversa; E A Eugenin; J W Berman
Journal:  J Neurosci Res       Date:  2005-08-01       Impact factor: 4.164

4.  Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version.

Authors:  Marc A Norman; David J Moore; Michael Taylor; Donald Franklin; Lucette Cysique; Chris Ake; Deborah Lazarretto; Florin Vaida; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2011-06-24       Impact factor: 2.475

5.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

6.  Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.

Authors:  Elizabeth C Mormino; Rebecca A Betensky; Trey Hedden; Aaron P Schultz; Rebecca E Amariglio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal:  JAMA Neurol       Date:  2014-11       Impact factor: 18.302

7.  Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy.

Authors:  Iain C Anthony; Stephen N Ramage; Frances W Carnie; Peter Simmonds; Jeanne E Bell
Journal:  Acta Neuropathol       Date:  2006-05-09       Impact factor: 17.088

8.  HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.

Authors:  Robert K Heaton; Donald R Franklin; Ronald J Ellis; J Allen McCutchan; Scott L Letendre; Shannon Leblanc; Stephanie H Corkran; Nichole A Duarte; David B Clifford; Steven P Woods; Ann C Collier; Christina M Marra; Susan Morgello; Monica Rivera Mindt; Michael J Taylor; Thomas D Marcotte; J Hampton Atkinson; Tanya Wolfson; Benjamin B Gelman; Justin C McArthur; David M Simpson; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Terry L Jernigan; Joseph Wong; Igor Grant
Journal:  J Neurovirol       Date:  2010-12-21       Impact factor: 2.643

9.  Beta amyloid levels in cerebrospinal fluid of HIV-infected people vary by exposure to antiretroviral therapy.

Authors:  Jerel Adam Fields; Mary K Swinton; Benchawanna Soontornniyomkij; Aliyah Carson; Cristian L Achim
Journal:  AIDS       Date:  2020-06-01       Impact factor: 4.632

10.  Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.

Authors:  Julia Peterson; Magnus Gisslen; Henrik Zetterberg; Dietmar Fuchs; Barbara L Shacklett; Lars Hagberg; Constantin T Yiannoutsos; Serena S Spudich; Richard W Price
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240
View more
  1 in total

1.  Patterns of Cerebrospinal Fluid Alzheimer's Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition.

Authors:  Mattia Trunfio; Cristiana Atzori; Marta Pasquero; Alessandro Di Stefano; Daniela Vai; Marco Nigra; Daniele Imperiale; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  Viruses       Date:  2022-04-04       Impact factor: 5.818
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.